Side-by-side · Research reference

SurvodutidevsTesofensine

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED25/54 cited

BPhase 3AUTO-DRAFTED10/40 cited

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

Tesofensine

SNDRI · Phase 3 obesity candidate

0.25–0.5 mgDaily doseAstrup 2008

9.2 kgWeight ↓ (24 wk)Astrup 2008

Phase 3Evidence levelAstrup 2008

Oral · Once daily morning

01Mechanism of Action

Parameter

Survodutide

Tesofensine

Primary target

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008

Pathway

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008

Downstream effect

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008

Feedback intact?

—

Origin

—

Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008

Antibody development

—

02Dosage Protocols

Parameter

Survodutide

Tesofensine

Standard dose

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

0.25–0.5 mg / dayAstrup 2008

Frequency

Once weekly

Once daily, morning

Route

SubcutaneousYathindra 2026

—

Evidence basis

Phase 2 RCT (obesity) · Phase 3 ongoing

Phase 2b + ongoing Phase 3Astrup 2008

Phase 2 findings

Significant weight loss and metabolic marker improvementYathindra 2026

—

MASH indication

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

—

Lower / starter dose

—

0.125 mg / day

Duration

—

24 weeks per studied cycle

Form

—

Oral capsule

Timing

—

Morning to avoid sleep disruption

Half-life

—

~9 days (very long)

03Metabolic / Fat Loss Evidence

Parameter

Survodutide

Tesofensine

Primary fat target

Total body weight, visceral adipose tissue

—

Weight loss mechanism

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

—

Phase 2 efficacy

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

—

Metabolic markers

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

—

MRI-PDFF reduction

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

—

Network meta-analysis

Favorable efficacy profile vs other glucagon receptor agonists

—

Hepatic requirement

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

—

Energy expenditure

Increased energy expenditure contributes to weight lossZimmermann 2026

—

Comparative efficacy

Network meta-analysis shows competitive efficacy in GRA class

—

04Side Effects & Safety

Parameter

Survodutide

Tesofensine

GI symptoms

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

—

Safety profile

Network meta-analysis: comparable safety to other GRAs

—

Serious adverse events

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

—

Injection site reactions

Expected with subcutaneous administration

—

Glucagon-related effects

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

—

Heart rate / BP

—

Dose-dependent ↑ HR + BPAstrup 2008

Insomnia

—

Dose-related; mitigate with morning timing

Dry mouth

—

Common

Nausea

—

Common

Mood changes

—

Anxiety / agitation possible

Cardiovascular events

—

Phase 3 trial monitoring; not yet FDA-cleared

Pregnancy / OB

—

Contraindicated

Absolute Contraindications

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Tesofensine

·Pregnancy / breastfeeding
·Severe cardiovascular disease
·Concurrent MAOI use

Relative Contraindications

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

Tesofensine

·Hypertension
·Anxiety disorder
·Insomnia

05Administration Protocol

Parameter

Survodutide

Tesofensine

1. Reconstitution

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

Oral capsule (investigational; not commercial).

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

Swallow whole with water, morning only.

3. Timing

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

Morning to mitigate insomnia. Do not dose evening.

4. Storage

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

Room temp ≤25 °C, dry place.

5. Needle

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.

Monitor BP + HR + mood. Avoid stimulants + MAOIs.